STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.

O'Dwyer, M E

STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. [electronic resource] - The Lancet. Oncology Dec 2000 - 207-11 p. digital

Publication Type: Journal Article; Review

1470-2045

10.1016/s1470-2045(00)00149-2 doi


Animals
Antineoplastic Agents--pharmacology
Benzamides
Clinical Trials, Phase I as Topic
Disease Models, Animal
Enzyme Inhibitors--pharmacology
Fusion Proteins, bcr-abl--drug effects
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--diagnosis
Piperazines--pharmacology
Protein-Tyrosine Kinases--antagonists & inhibitors
Pyrimidines--pharmacology
Sensitivity and Specificity